New Trends in Esophageal Cancer Management

Gronnier, Caroline; Collet, Denis

doi:10.3390/cancers13123030

Cited by 14 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is a literature gap in this area regarding esophageal surgery, indirect evidence could be drawn from the colorectal surgery field, in which CRP levels could be used, among other parameters, to monitor patients postoperatively and assist in the discharge decision [ 29 ]. Although the ERAS protocol does not include a recommendation regarding the discharge time point, recent trends of increased application of ERAS protocol are associated with a shorter length of stay [ 30 ]. Therefore, our suggested cutoff value of CRP in POD 8 could be used, among other clinical factors, as a criterion for early discharge in patients undergoing ERAS protocol.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the use of inflammatory biomarkers in the early detection of anastomotic leakage after esophagectomy: A retrospective analysis

Azer

Miftode

Bockhorn

et al. 2022

Surgery Open Science

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Evaluation of the use of inflammatory biomarkers in the early detection of anastomotic leakage after esophagectomy: A retrospective analysis

Azer

Miftode

Bockhorn

et al. 2022

Surgery Open Science

View full text Add to dashboard Cite

“…While even for patients who received comprehensive therapy, such as radical esophagectomy with or without neoadjuvant therapy, locoregional recurrence or distant metastasis remains the main failure mode after treatment [2,3]. For patients with a locally advanced stage who have lost the opportunity for surgical resection or refuse to receive surgical treatment and those who experienced treatment failure after surgical resection, radiotherapy with or without chemotherapy remains one of the main treatment modalities; however, its e cacy is far from satisfactory [4,5]. tube implantation.…”

Section: Introductionmentioning

confidence: 99%

Immune checkpoint inhibitors combined with radiotherapy/chemoradiotherapy in treating locally advanced or recurrent/metastatic esophageal squamous cell carcinoma: A real-world study

Zhao

Gao

Wen

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: This study was designed to investigate the prognostic factors for immune checkpoint inhibitors (ICIs) combined utilization with radiotherapy (RT)/chemoradiotherapy (CRT) and to evaluate their toxicity in locally advanced or recurrent/metastatic esophageal squamous cell carcinoma (LA/RM ESCC). Methods: In this study, 198 LA/RM ESCC patients who received ICIs combined with RT/CRT in the Department of Radiotherapy of the Fourth Hospital of Hebei Medical University were retrospectively analyzed. Univariate and multivariate analyses were performed to determine the prognostic factors for overall survival (OS) and progression-free survival (PFS). Subgroup analysis was utilized to explore the prognostic factors, the treatment respond and treatment-related adverse events (trAEs) were analyzed. Results: The median OS and PFS were 30.4 months (95% confidence interval [CI]: 15.1–45.7 months) and 15.3 months (95% CI: 12.8–17.8 months), respectively. The median OS and PFS for patients achieving objective respond (ORR group, including complete response and partial response) were 50.8 months (95% CI: 25.8–75.7 months) and 20.5 months (95% CI: 14.1–27.0), respectively, which were higher than those in non-ORR group (OSnon-ORR:17.5 months, 95% CI: 14.0–21.0; χ2 = 13.881, P < 0.001; PFSnon-ORR: 12.1 months, 95% CI: 10.1–14.1, χ2 = 10.676, P = 0.001). Results from subgroup analysis illustrated combined ICIs with radiotherapy could improve the treatment respond (χ2 = 47.725, P = 0.000). The OS rate (χ2 = 18.836, P < 0.001) and PFS rate (χ2 = 6.881, P = 0.009) were significantly higher in the whole-lesion radiotherapy group than in the partial-lesion radiotherapy group. Multivariate analysis showed that the number of immune cycles, the coverage of radiotherapy target, the modality of ICIs-combination therapy and treatment response were independent prognosis factors for OS (hazard ratio [HR] = 0.512, 2.043, 1.889, and 1.912, respectively; P = 0.001, 0.001, 0.013, and 0.002, respectively). Radiotherapy coverage and treatment response were independent factors for PFS (HR = 1.478 and 1.597, respectively; P = 0.032 and 0.012, respectively). In the entire study population, 83 patients (41.9%) had ≥ grade 2 trAEs. Conclusions: ICIs combined with radiotherapy/chemoradiotherapy are safe and effective in LA/RM ESCC patients. The addition of radiotherapy could improve the treatment respond and whole-lesion radiotherapy improve prognosis compared with partial-lesion radiotherapy group. The number of immunotherapy cycles and treatment response are the main factors affecting prognosis.

show abstract

“…In China, large urban-rural disparities had seen in morbidity and mortality, with high indicators in rural areas during 2005 to 2015 2 . Thanks to the progressive treatment mode in EC, the incidence and mortality of EC have been decreasing year by year 1 , 3 , 4 .…”

Section: Introductionmentioning

confidence: 99%

What Causes Death in Esophageal Cancer Patients Other Than the Cancer Itself: A Large Population-Based Analysis

et al. 2022

View full text Add to dashboard Cite

Background: Researches on noncancer causes of death in patients with esophageal cancer (EC) are not in-depth. The objective of this paper is to broadly and deeply explore the causes of death in patients with EC, especially noncancer causes. Methods: Information about the demographics, tumor-related characteristics, and causes of death of patients with EC who met the inclusion criteria were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Calculated standardized mortality ratio (SMR) for all causes of death at different follow-up times and performed subgroup analyses. Results: In total, 63,560 patients with EC were retrieved from the public database. And 52,503 died during the follow-up period. Most deaths were due to EC itself within 5 years after diagnosis, but over 10 years, 59% EC patients died from noncancer causes. Cardiovascular disease was the major noncancer cause of death in patients with EC, accounting for 43%. Suicide and self-injury (2%) of EC patients should not be ignored. During the 1-year follow-up period, patients with EC had statistically highest risk of death from septicemia (SMR: 7.61; 95% CI: 6.38-9.00). Within more than 10 years after EC diagnosis, more and more patients died from chronic obstructive pulmonary disease (SMR: 2.38; 95% CI: 1.79-3.10). Conclusions: Although most patients with EC still died from the cancer itself, the role of noncancer causes of death should not be underestimated. These prompt clinicians to pay more attention to the risk of death caused by these noncancer causes, which can provide relevant measures in advance to intervene.

show abstract

New Trends in Esophageal Cancer Management

Abstract: Esophageal cancer (EC) is a condition with a five-year survival rate of around 15% for all stages considered [...]

Cited by 14 publications

References 37 publications

Evaluation of the use of inflammatory biomarkers in the early detection of anastomotic leakage after esophagectomy: A retrospective analysis

Evaluation of the use of inflammatory biomarkers in the early detection of anastomotic leakage after esophagectomy: A retrospective analysis

Immune checkpoint inhibitors combined with radiotherapy/chemoradiotherapy in treating locally advanced or recurrent/metastatic esophageal squamous cell carcinoma: A real-world study

What Causes Death in Esophageal Cancer Patients Other Than the Cancer Itself: A Large Population-Based Analysis

Contact Info

Product

Resources

About